Iodotyrosine deiodinase defect identified via genome-wide approach

Agnès Burniat1, Isabelle Pirson, Catheline Vilain

  • 1Department of Endocrinology, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium. aburniat@ulb.ac.be

Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...